Case Report

A Case of Primary Subglottic Malignant Melanoma with a Successful Surgical Treatment

Shahzad Ahmad, Mahmoud Abdelghany, Curtis Goldblatt, Owen Stark, and Nicholas Masciotra

1 Department of Medicine, Conemaugh Memorial Medical Center, Johnstown, PA 15905, USA
2 Department of Anatomic and Clinical Pathology, Conemaugh Memorial Medical Center, Johnstown, PA 15905, USA
3 Department of Radiology, Conemaugh Memorial Medical Center, Johnstown, PA 15905, USA
4 Department of Otolaryngology, Conemaugh Memorial Medical Center, Johnstown, PA 15905, USA

Correspondence should be addressed to Mahmoud Abdelghany; mabdelgh@conemaugh.org

Received 14 March 2014; Accepted 27 May 2014; Published 8 June 2014

Academic Editor: Gerassimos P. Vandoros

Copyright © 2014 Shahzad Ahmad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Primary subglottic malignant melanoma is a very rare and underdiagnosed neoplasm. We are reporting a case of primary malignant melanoma of subglottic mucosa in a 78-year-old woman who presented to our hospital with shortness of breath and hoarseness of voice. Laryngoscopy and excisional biopsy along with immunoreactivity to S-100 and human melanoma black-45 (HMB-45) confirmed the diagnosis. The patient was treated with laryngectomy followed by radiotherapy. Five years following surgical treatment, she continues to be asymptomatic. To our knowledge, there is only one reported case of primary malignant melanoma of subglottic mucosa in the medical literatures.

1. Introduction

Although most melanomas are cutaneous in origin, primary malignant melanoma does occasionally arise from noncutaneous tissues that contain melanocytes, such as leptomeninges, uvea, and gastrointestinal, respiratory, and genitourinary tracts [1]. The least common of all the aforementioned sites is the subglottic mucosa of larynx. There are less than 60 cases of primary malignant melanoma of the larynx [2] and only one case of primary subglottic melanoma reported in the medical literatures [1].

2. Case

A 78-year-old white woman, with no significant past medical history, presented to our hospital because of progressively worsening dyspnea and hoarseness of voice for two months. She denied any other symptoms including dysphagia, odynophagia, and otalgia. At first, her symptoms were attributed to chronic obstructive pulmonary disease (COPD), and she was started on oxygen therapy and multiple medications for COPD, but her symptoms kept worsening. On presentation, the patient was severely dyspneic and wheezing with decreased air entry bilaterally. Computed tomography (CT) scan of the chest and neck showed a subglottic lesion that was obstructing the airway (Figure 1). The patient's respiratory status continued to deteriorate, so an elective tracheostomy was performed to secure airway. Later, direct laryngoscopy showed an ulcerated lesion emanating from the left anterior aspect of the subglottis. Biopsy of the ulcerated lesion revealed sheets of malignant melanin containing cells involving the overlying squamous mucosa and extending into the lamina propria. The nuclei were significantly pleomorphic with prominent nucleoli and mitotic figures (Figure 2).

The immunoprofile of neoplastic cells was strongly positive for tyrosinase, HMB-45, S-100, and P53 (Figures 3 and 4) and negative for cytokeratin 5/6 and CD34. In order to differentiate the primary from metastatic melanoma, axon 15 BRAF and NRAS testing were performed. The tumor was negative for both of them, which strongly suggested a primary...
Figure 1: CT scan (sagittal image) of the neck with contrast performed after the initial tracheostomy demonstrates an ovoid mass (arrow) obstructing nearly the entire lumen of the airway. The mass measures 22 mm craniocaudally by 11 mm anteroposteriorly.

Figure 2: Hematoxylin and eosin (H&E) stained 40x objective photomicrograph shows discohesive malignant neoplasm with enlarged hyperchromatic pleomorphic nuclei and eosinophilic nucleoli and surrounding pale cytoplasm.

Figure 3: Melanin A stained 40x objective photomicrograph shows malignant cells stains strongly positive for melanin A.

Figure 4: Human melanoma black-45 (HMB-45) stained 40x objective photomicrograph shows malignant cells stains strongly positive for HMB-45.

The patient usually presents with hoarseness of voice, shortness of breath, dysphagia, and sore throat. Differentiation of primary from the secondary lesion may be challenging, especially because of the fact that melanoma may disappear from primary site after metastasis [1, 7, 8]. On gross examination, malignant melanoma may have slate gray, brown, or black pigmentation, which may be a clue to diagnosis. Actual diagnosis cannot be made without histopathological examination of tissue sections [7]. Hematoxylin and eosin staining typically shows pleomorphic, epithelioid, and/or spindle shaped malignant cells extending into adjacent lateral and overlying mucosa. Cells often contain dark brown cytoplasmic and nuclear melanin [8]; however, some lesions are amelanotic and others demonstrate features similar to malignant neoplasm of different origins [7]. Presence of melanoma markers as S-100, HMB-45, Melan-A, and PNL-2 must therefore be demonstrated through immunohistochemical staining to confirm the diagnosis [1, 8]. Electron microscopy may identify the presence of melanosomes or premelanosomes. PET scan and/or magnetic resonance imaging (MRI) can be used to stage primary melanoma [8].

It is obvious that mucosal melanomas are more aggressive and have worse prognosis as compared to their cutaneous counterparts with overall 5-year survival of less than 20% [9]. Poor prognosis is typically associated with early presentation of distant metastases despite adequate locoregional control.

3. Discussion

Mucosal melanomas represent 1.3% of all melanomas [2, 3]. Majority of patients are white males in their sixth or seventh decade of life with only two reports of Asian individuals [2, 4]. Smoking is a major risk factor [2, 5], but exposure to sunlight, human papilloma virus, chronic irritants, and carcinogenic compounds are also presumed to play a role [2, 6]. Recently, several studies reported that malignant melanomas are related to an altered immune system, and many genes have been speculated to be involved in its pathogenesis but this is not confirmed yet [2].
Most of mucosal melanomas already have distant micrometastases at the time of diagnosis [1]. The treatment for mucosal melanomas of head and neck, including laryngeal lesions, is complete surgical excision, but sometimes it is difficult because of proximity of tumor to critical structures. Postoperative radiation therapy to the affected area has been shown to improve local control in several retrospective series [10, 12]. Whether this improvement translates to an improvement in prognosis remains unclear. Initial results with traditional chemotherapeutic agents in both cutaneous and mucosal variants of melanoma have been disappointing [12, 13]. Recent studies have shown an involvement of immune system dysregulation in pathophysiology of mucosal melanomas with identification of certain genes like IL17A and CD70 [2]. This can be a major finding towards development of effective adjuvant immunotherapy for the treatment of melanomas.

Primary subglottic melanoma is an exceptionally rare neoplasm with early distant metastases and aggressive fatal course. Early diagnosis and proper treatment are crucial for survival. Physicians should keep a low threshold of suspicion for diagnosis of this rare tumor especially in old age. We believe that every case should be reported for better understanding of this extremely rare disease.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Shahzad Ahmad and Mahmoud Abdelghany contributed equally to the writing of this paper, and they are considered the first authors.

Acknowledgment

The authors acknowledge Mary Ann Renda, RN, for her help in the preparation of this paper.

References

[1] S. Zaghi, D. Pouldar, C. Lai, and D. K. Chhetri, “Subglottic presentation of a rare tumor: primary or metastatic?” JAMA Otolaryngology—Head and Neck Surgery, vol. 139, no. 7, pp. 739–740, 2013.

[2] S. Sirikanjanapong, B. Lanson, M. Amin, F. Martinuk, H. Kamino, and B. Y. Wang, “Collision tumor of primary laryngeal mucosal melanoma and invasive squamous cell carcinoma with IL-17A and CD70 gene over-expression,” Head and Neck Pathology, vol. 4, no. 4, pp. 295–299, 2010.

[3] A. E. Chang, L. H. Karnell, and H. R. Menck, “The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society,” Cancer, vol. 83, no. 8, pp. 1664–1678, 1998.

[4] B. M. Wenig, “Laryngeal mucosal malignant melanoma. A clinicopathologic, immunohistochemical, and ultrastructural study of four patients and a review of the literature,” Cancer, vol. 75, no. 7, pp. 1568–1577, 1995.

[5] V. E. Reuter and J. M. Woodruff, “Melanoma of the larynx,” Laryngoscope, vol. 96, no. 4, pp. 389–393, 1986.

[6] M. Wagner, C. G. Morris, J. W. Werning, and W. M. Mendenhall, “Mucosal melanoma of the head and neck,” The American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 31, no. 1, pp. 43–48, 2008.

[7] H. M. Amin, G. J. Petruzzelli, A. N. Husain, and B. J. Nickoloff, “Primary malignant melanoma of the larynx,” Archives of Pathology and Laboratory Medicine, vol. 125, no. 2, pp. 271–273, 2001.

[8] R. Durai and S. Hashmi, “Primary malignant melanoma of the epiglottis: a rare presentation,” Ear, Nose and Throat Journal, vol. 85, no. 4, pp. 274–277, 2006.

[9] T. Terada, N. Saeke, K. Tob et al., “Primary malignant melanoma of the larynx: a case report and literature review,” Auris Nasus Larynx, vol. 34, no. 1, pp. 105–110, 2007.

[10] K. Saigal, D. T. Weed, I. M. Reis, A. M. Markoe, A. H. Wolfson, and J. Nguyen-Sperry, “Mucosal melanomas of the head and neck: the role of postoperative radiation therapy,” ISRN Oncology, vol. 2012, Article ID 785131, 7 pages, 2012.

[11] G. Bachar, S. L. Kwock, B. O’Sullivan et al., “Mucosal melanomas of the head and neck: the Princess Margaret Hospital experience,” Head and Neck, vol. 30, no. 10, pp. 1325–1331, 2008.

[12] M. Krengli, B. A. Jereczek-Fossa, J. H. A. M. Kaanders, L. Masini, D. Beldi, and R. Orecchia, “What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck?” Critical Reviews in Oncology/Hematology, vol. 65, no. 2, pp. 121–128, 2008.

[13] J. E. Medina, A. Ferlito, P. K. Pellitteri et al., “Current management of mucosal melanoma of the head and neck,” Journal of Surgical Oncology, vol. 83, no. 2, pp. 116–122, 2003.